Wave Life Sciences to Present at the Chardan 7th Annual Genetic Medicines Conference
September 25, 2023 08:30 ET
|
Wave Life Sciences USA, Inc.
CAMBRIDGE, Mass., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage RNA medicines company committed to delivering life-changing treatments for people...
Wave Life Sciences to Present at the H.C. Wainwright 25th Annual Global Investment Conference
September 06, 2023 08:30 ET
|
Wave Life Sciences USA, Inc.
CAMBRIDGE, Mass., Sept. 06, 2023 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage RNA medicines company committed to delivering life-changing treatments for people...
Wave Life Sciences Announces Submission of First Clinical Trial Application for WVE-006, the First-ever RNA Editing Clinical Candidate, and Plans for Upcoming Virtual “R&D Day”
September 05, 2023 07:30 ET
|
Wave Life Sciences USA, Inc.
WVE-006 is the first-ever RNA editing program to enter clinical development and is designed to restore production and circulation of functional, wild-type alpha-1 antitrypsin (AAT) protein and reduce...
Wave Life Sciences Reports Second Quarter 2023 Financial Results and Provides Business Update
August 03, 2023 07:30 ET
|
Wave Life Sciences USA, Inc.
Preparing for imminent submission of clinical trial applications (CTAs) for GalNAc-conjugated AATD candidate (WVE-006), the industry’s first RNA editing clinical candidate Novel DMD therapeutic...
Wave Life Sciences Second Quarter 2023 Financial Results Scheduled for August 3, 2023
July 27, 2023 08:30 ET
|
Wave Life Sciences USA, Inc.
CAMBRIDGE, Mass., July 27, 2023 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage RNA medicines company committed to delivering life-changing treatments for people battling...
Wave Life Sciences Joins the Russell 2000® and Russell 3000® Indexes
June 26, 2023 08:30 ET
|
Wave Life Sciences USA, Inc.
CAMBRIDGE, Mass., June 26, 2023 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage RNA medicines company committed to delivering life-changing treatments for people battling...
Wave Life Sciences Announces Topline Results from Phase 1b/2a FOCUS-C9 Study of WVE-004 for C9orf72-associated Amyotrophic Lateral Sclerosis and Frontotemporal Dementia
May 23, 2023 07:30 ET
|
Wave Life Sciences USA, Inc.
Potent and durable target engagement observed across cohorts, including with 10 mg doses administered every 12 weeks which were also generally safe and well-tolerated WVE-004 did not show clinical...
Wave Life Sciences to Highlight Leading RNA Editing Capability and Multimodal Discovery and Development Platform at ASGCT 26th Annual Meeting
May 16, 2023 08:30 ET
|
Wave Life Sciences USA, Inc.
Presentations include new data showing WVE-006 improved markers of liver disease in mice; WVE-006 is a first-in-class RNA editing therapeutic for alpha-1 antitrypsin deficiency (AATD) which is...
Wave Life Sciences Reports First Quarter 2023 Financial Results and Provides Business Update
May 03, 2023 07:30 ET
|
Wave Life Sciences USA, Inc.
Emerging leader in RNA medicines with multi-modal discovery and development platform and first-in-class RNA editing programs Rapidly advancing toward 2023 CTA submissions and first-in-human...
Wave Life Sciences First Quarter 2023 Financial Results Scheduled for May 3, 2023
April 26, 2023 08:30 ET
|
Wave Life Sciences USA, Inc.
CAMBRIDGE, Mass., April 26, 2023 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people...